Vedolizumab Achieves Steroid-Free Clearance in Colitis

The VERDICT trial links deeper disease clearance in ulcerative colitis patients to longer delays before complications develop.

Updated on Nov. 11, 2026 in Heart Disease

Vedolizumab Achieves Steroid-Free Clearance in Colitis

Intravenous vedolizumab achieved corticosteroid-free disease clearance in ulcerative colitis patients by 16 weeks, according to the VERDICT trial presented at United European Gastroenterology Week. Almost 60% of patients reached their assigned corticosteroid-free target by 48 weeks.

Why it matters

Ulcerative colitis treatment has increasingly focused on achieving deeper disease control rather than symptom relief alone. The trial is the first prospective study of vedolizumab testing whether clearance delays ulcerative colitis-related complications.

The VERDICT trial, a prospective study of intravenous vedolizumab, reported corticosteroid-free disease clearance by 16 weeks, with almost 60% of patients reaching their assigned target by 48 weeks. The source does not report the sample size or the statistical magnitude of the difference in complication timing between groups.

The players

Takeda

Takeda is a global pharmaceutical company that markets vedolizumab, a biologic therapy for inflammatory bowel disease.

Alimentiv

Alimentiv is a clinical research organization involved in gastrointestinal and inflammatory disease trials.

The details

Patients with ulcerative colitis received intravenous vedolizumab and were assigned to either a disease clearance group or a symptomatic remission group. Patients in the disease clearance group experienced a longer time to ulcerative colitis-related complications than those in the symptomatic remission group.

Timeline

  1. Corticosteroid-free disease clearance was reached by 16 weeks.

  2. Almost 60% of patients achieved the corticosteroid-free target by 48 weeks.

Health Landscape

The VERDICT trial extends vedolizumab research by testing whether deeper disease clearance, rather than symptom relief, delays ulcerative colitis complications. The approach reflects a broader shift in inflammatory bowel disease care toward treating disease activity more fully.

Patients with ulcerative colitis may eventually have treatment options that aim for steroid-free remission rather than symptom control alone. The study does not establish whether these results will change routine prescribing.

The takeaway

Deeper disease control may matter beyond symptom relief, and the VERDICT results suggest clearance could delay complications in ulcerative colitis. Further trials will be needed to confirm whether this approach changes long-term outcomes.

Further reading

Explore more heart disease research to see how treatment goals are evaluated across chronic conditions.

Source note: This article includes information reported by Healio.